Canada has submitted the first legislative review of the Tobacco and Vaping Products Act (TVPA) to Parliament. According to a government press release, the review primarily focuses on provisions in the TVPA related to electronic cigarettes, including the obligation for a legislative review three years after its implementation, followed by a biennial review.
The review proposed by the Minister of Mental Health and Addictions and Deputy Minister of Health, Carolyn Bennett, is based on a public consultation and existing evidence, including scientific journals with peer review, population surveys, and public opinion research.
Electronic cigarette products provide a less harmful source of nicotine for 3.8 million Canadians and can help people quit smoking. However, these products are not without risks, especially for young people and non-smokers, according to Bennett. The first legislative review of the Tobacco and Vaping Products Act is a valuable opportunity to evaluate progress in addressing youth vaping, but more work needs to be done. The government will continue to work on developing the right protective measures to prevent young people from the harms of e-cigarettes and nicotine addiction.
The review findings indicate that the TVPA is making progress towards achieving its set goals related to e-cigarettes. It is noteworthy that in the past two years, the use of e-cigarettes among young people has been rapidly increasing but has now stabilized at a relatively high level, prompting the need for more efforts to protect young people.
The TVPA, implemented in 2018, was designed to address the increasing availability of e-cigarette products in Canada and help ensure Canadians are aware of the associated health risks and protected. It regulates the manufacturing, sale, labeling, and promotion of e-cigarette products sold in Canada. The TVPA requires legislative reviews three years after coming into effect, and every two years thereafter. Regular reviews provide a way to examine and address tobacco and/or e-cigarette related issues that may arise over time. The review was conducted through a public consultation from March 16, 2022, to April 27, 2022. Canadians were encouraged to provide feedback on the TVPA legislative review discussion paper. As part of the public consultation, Health Canada received 3,092 submissions. For information on smoking cessation programs in Canada, visit Canada.ca/quitsmoking. Health Canada provides financial support to addiction and mental health centers to develop low-risk nicotine use guidelines. The guidelines recommend smokers try approved cessation treatments first before considering e-cigarettes. The review also identified areas where action may be taken, including examining youth access to e-cigarette products and promoting the potential benefits of e-cigarettes as a less harmful source of nicotine for smokers.
The report suggests that smokers should switch entirely to electronic cigarettes to address health risks, strengthen compliance and enforcement, and address uncertainties around science and product development, in order to gain a better understanding of the e-cigarette market and its impact on health.
2FIRSTS will continue to cover this topic and provide updates on the "2FIRSTSAPP". Scan the QR code below to download the app.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
